Literature DB >> 18195163

Trophoblasts reduce the vascular smooth muscle cell proatherogenic response.

Lydia Hering1, Florian Herse, Stefan Verlohren, Joon-Keun Park, Maren Wellner, Fatimunnisa Qadri, Robert Pijnenborg, Anne C Staff, Berthold Huppertz, Dominik N Muller, Friedrich C Luft, Ralf Dechend.   

Abstract

Maternal spiral artery remodeling is the consequence of controlled trophoblast invasive interaction with the maternal cellular environment and is fundamentally important for successful placentation. In preeclampsia, trophoblast invasion is shallow, remodeling is incomplete, and vessels develop an inflammatory appearance, termed "acute atherosis." We noted that, in our preeclampsia, human renin-human angiotensinogen transgenic rat model, complement component 3 (C3), and tumor necrosis factor-alpha were upregulated and heavily expressed in atherotic uteroplacental vessels. We next used coculture involving human trophoblasts, rat vascular smooth muscle cells (VSMCs), and human VSMCs to observe VSMC-trophoblast regulatory interactions. Tumor necrosis factor-alpha induced complement C3 and interleukin-6 expression in VSMCs. We found that trophoblasts were able to reduce VSMC C3 and interleukin-6 expression after the VSMCs were stimulated with tumor necrosis factor-alpha. However, a direct VSMC-trophoblast cell-cell contact was necessary for this anti-inflammatory response. We also studied double-transgenic VSMCs that express inflammatory components and exhibit accelerated proliferation ("synthetic" phenotype). Trophoblasts could not downregulate C3 in these cells. We then examined uteroplacental tissues from preeclamptic and control patients. In control deciduas, only traces of C3 staining were observed, and vessels were thin walled without thrombus formation. In preeclampsia, the decidual vessels showed atherosis, thrombus formation, and C3 expression. Our data suggest that fetally derived trophoblasts require direct cell-cell contact with maternally derived VSMCs to downregulate VSMC C3 and interleukin-6 expression and to avoid atherosis. The findings also implicate C3 in the placental vasculopathy observed in preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195163     DOI: 10.1161/HYPERTENSIONAHA.107.102905

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

1.  Characterization of antibody specificities associated with preeclampsia.

Authors:  Serra E Elliott; Nicholas F Parchim; Chen Liu; Yang Xia; Rodney E Kellems; Alex R Soffici; Patrick S Daugherty
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

2.  Chromosome-substituted rat strains provide insights into the genetics of placentation.

Authors:  Toshihiro Konno; Lea A Rempel; M A Karim Rumi; Amanda R Graham; Kazuo Asanoma; Stephen J Renaud; Michael J Soares
Journal:  Physiol Genomics       Date:  2011-06-07       Impact factor: 3.107

Review 3.  Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension.

Authors:  Florian Herse; Babbette LaMarca
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

Review 4.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

Review 5.  Regulatory pathways controlling the endovascular invasive trophoblast cell lineage.

Authors:  Michael J Soares; Damayanti Chakraborty; Stephen J Renaud; Kaiyu Kubota; Pengli Bu; Toshihiro Konno; M A Karim Rumi
Journal:  J Reprod Dev       Date:  2012       Impact factor: 2.214

Review 6.  Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.

Authors:  Ai-Ris Y Collier; Laura A Smith; S Ananth Karumanchi
Journal:  Hum Immunol       Date:  2021-02-05       Impact factor: 2.850

7.  NF-κB-responsive miR-155 induces functional impairment of vascular smooth muscle cells by downregulating soluble guanylyl cyclase.

Authors:  Minsik Park; Seunghwan Choi; Suji Kim; Joohwan Kim; Dong-Keon Lee; Wonjin Park; Taesam Kim; Jiwon Jung; Jong Yun Hwang; Moo-Ho Won; Sungwoo Ryoo; Seung Goo Kang; Kwon-Soo Ha; Young-Guen Kwon; Young-Myeong Kim
Journal:  Exp Mol Med       Date:  2019-02-15       Impact factor: 8.718

Review 8.  Dysregulation of Complement Activation and Placental Dysfunction: A Potential Target to Treat Preeclampsia?

Authors:  E Pierik; Jelmer R Prins; Harry van Goor; Gustaaf A Dekker; Mohamed R Daha; Marc A J Seelen; Sicco A Scherjon
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

Review 9.  Acute Atherosis Lesions at the Fetal-Maternal Border: Current Knowledge and Implications for Maternal Cardiovascular Health.

Authors:  Daniel Pitz Jacobsen; Heidi Elisabeth Fjeldstad; Guro Mørk Johnsen; Ingrid Knutsdotter Fosheim; Kjartan Moe; Patji Alnæs-Katjavivi; Ralf Dechend; Meryam Sugulle; Anne Cathrine Staff
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

10.  Iodine deficiency in pregnancy along a concentration gradient is associated with increased severity of preeclampsia in rural Eastern Cape, South Africa.

Authors:  Charles Bitamazire Businge; Benjamin Longo-Mbenza; Andre Pascal Kengne
Journal:  BMC Pregnancy Childbirth       Date:  2022-02-04       Impact factor: 3.007

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.